On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveﾙ (casirivimab and imdevimab) in patients hospitalised with COVID-19.

The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of their own (seronegative) and who required low-flow or no supplemental oxygen.